JOINN Laboratories reports Q3 2025 financials, proposes board changes

JOINN Laboratories (China) announced its 2025 third quarterly report, detailing revenue of RMB316,386,318.62 for the quarter, a 34.87% decrease year-on-year. Net profit attributable to shareholders was RMB19,773,668.63, an 80.11% decrease. The decrease was primarily attributed to market competition impacting sales order prices and compressing profit margins in laboratory services. Despite these figures, the company secured new orders totaling approximately RMB1.64 bn during the first three quarters, with total orders reaching RMB2.5 bn by the end of the reporting period.

In parallel, JOINN Laboratories is proposing amendments to its articles of association and rules of procedures for the general meeting of shareholders. These changes include a revised board size, the removal of the supervisory committee, and updated regulations for director elections and share buybacks, among others, to align with the amended Company Law of the PRC effective July 1, 2024. Shareholders will vote on these amendments by special resolution at an extraordinary general meeting.

Additionally, the company is revising annual caps for its continuing connected transactions under the 2024 property service agreements. Due to increased energy demands, the annual caps for property management services provided by Beijing Joinn Biologics are proposed to be revised to RMB6m for 2025 and RMB6.5m for 2026. These transactions, involving an associate of controlling shareholders, will be subject to reporting, announcement, and annual review.